India to Malaysia: Emtricitabine Export Trade Route

The India to Malaysia Emtricitabine corridor is one of India's established pharmaceutical export routes, with 54 shipments documented worth a combined $2.4M USD. The route is dominated by MYLAN LABORATORIES LIMITED, which alone accounts for roughly 53% of all export value, reflecting the consolidated nature of India's emtricitabine manufacturing sector.

Across 10 active suppliers, the average shipment value stands at $44.3K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (67%) and air (17%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during October–December, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 32.5%, placing it at rank #6 among India's top emtricitabine export destinations globally.

On the import side, key buyers of Indian emtricitabine in Malaysia include PAHANG PHARMACY SDN BHD,, PAHANG PHARMACY SDN BHD, NA and 10 others. PAHANG PHARMACY SDN BHD, is the single largest importer with 7 shipments valued at $661.6K USD.

India's emtricitabine exports to Malaysia are driven primarily by a handful of large-scale manufacturers. MYLAN LABORATORIES LIMITED with 21 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 10 active exporters signals a competitive but concentrated market — buyers in Malaysia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED, AUROBINDO PHARMA LTD — together account for 93% of total trade value on this route. The average shipment value of $44.3K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as (ricovir- em) tenofovir disoproxil fumarate 300 mg+ emtricitabine 200 mg tab(30s) (60000 packs x 30's = 1800000 nos ) and ricovir em tenofovir disoproxil fumarate 300 mg emtricitabine 200mgtab 30 s 60000 packs x 30 s 1800000 nos, suggesting that buyers in Malaysia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, PAHANG PHARMACY SDN BHD, is the largest importer with 7 shipments worth $661.6K USD — representing 28% of all emtricitabine imports from India on this route. A total of 13 buyers are active on this corridor.